Research Topics
| F H SchroderSummaryCountry: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?F H Schroder
Department of Urology, Erasmus University and Academic Hospital Rotterdam, Rotterdam, The Netherlands
Prostate 42:107-15. 2000..This paper presents a rationale for the use of prostate-specific antigen (PSA) in clinical trials of progressive prostate cancer under endocrine treatment...- The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section RotterdamF H Schroder
Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
Eur Urol 35:539-43. 1999..Preliminary results with respect to the first round of screening in the Rotterdam area relating to 32,000 randomized men are presented. Evidence of effectiveness of screening through other studies and mechanisms is discussed... - Antiandrogens as monotherapy for prostate cancerF H Schroder
Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
Eur Urol 34:12-7. 1998..No difference was seen in the preservation of sexual functioning. Quality of life issues are becoming increasingly important and thus antiandrogen monotherapy may become more widely used in the management of prostate cancer... - Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate CancerF H Schroder
Department of Urology, Erasmus University, Rotterdam, The Netherlands
J Natl Cancer Inst 90:1817-23. 1998..Therefore, we evaluated the usefulness of DRE as a stand-alone screening test and in conjunction with measured serum prostate-specific antigen (PSA) levels of 0-3.9 ng/mL and transrectal ultrasonography (TRUS)... 
Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft modelJ Jongsma
Department of Urology, Erasmus University, Rotterdam, The Netherlands
Am J Pathol 154:543-51. 1999..The strictly androgen-independent NE cells that were still present after 21 days differentiated mainly from G0-phase-arrested cells...- The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomyM A Noordzij
Departments of Urology and Pathology, Erasmus University, 3000 DR Rotterdam, The Netherlands
Clin Cancer Res 3:805-15. 1997..Loss of CD44s expression in prostate adenocarcinoma predicts a poor prognosis, independent of stage and grade... - Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region)R Kranse
Department of Urology, Dijkzigt Academic Hospital, Rotterdam, The Netherlands
Prostate 39:316-22. 1999..All men with a PSA > or =4 ng/ml and/or a suspicious DRE and/or a suspicious TRUS are biopsied... - Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examinationF H Schroder
Department of Urology, Erasmus University and Academic Hospital Rotterdam, Rotterdam, The Netherlands
Urology 57:83-90. 2001..0 ng/mL or greater as the only indication for prostate biopsy with omission of the digital rectal examination (DRE)... - Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml)A N Vis
Department of Pathology, Josephine Nefkens Institute, Erasmus University, Rotterdam, The Netherlands
Prostate 47:252-61. 2001..The value of rectal examination as initial screening test for prostate cancer at low PSA values (0.0-3.9 ng/ml) was determined by evaluating the number and tumor characteristics of the cancers detected... - Lectin-cytochemistry of experimental rat nephrolithiasisW C de Bruijn
AEM Unit, Clinical Pathology Institute, Erasmus University, Rotterdam, The Netherlands
Scanning Microsc 10:557-76. 1996..WGA/Au-10 nm reaction products mark a crystal matrix component inside intratubular and retained crystals. A similar matrix was also marked by an alpha-osteopontin (alpha OPN/Au-10 nm) reaction product... - Pure antiandrogens as monotherapy in prospective studies of prostatic carcinomaF H Schroder
Department of Urology, Erasmus University, Rotterdam, The Netherlands
Prog Clin Biol Res 359:93-103; discussion 105-7. 1990.... - The story of the European Randomized Study of Screening for Prostate CancerF H Schroder
Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands
BJU Int 92:1-13. 2003 - Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: tumours that recur in time display an intermediate genetic status between non-persistent and metastatic tumoursJ C Alers
Department of Pathology, Eramus University, Rotterdam, The Netherlands
J Pathol 185:273-83. 1998..03). These data suggest that cancers which recur in time display an intermediate position between tumours of disease-free patients and metastatic cancers... - Defining the window of opportunity in screening for prostate cancer: validation of a predictive tumor classification modelA N Vis
Department of Pathology, Josephine Nefkens Institute, Erasmus University, P O Box 1738, 3000 DR Rotterdam, The Netherlands
Prostate 46:154-62. 2001..We investigated whether categorization of prostate cancers into different prognostic subgroups is feasible... - Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic featuresJ C Alers
Department of Pathology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
Am J Pathol 158:399-406. 2001..Finally, early localized tumors, as detected by screening programs, harbor cancers with aggressive genetic characteristics... - Androgen-independent growth is induced by neuropeptides in human prostate cancer cell linesJ Jongsma
Department of Experimental Urology, Erasmus University, Rotterdam, The Netherlands
Prostate 42:34-44. 2000..This may be caused by altered specificity of the androgen receptor (AR), by ligand-independent stimulation of the AR, or by paracrine growth modulation by neuropeptides secreted by neuroendocrine (NE) cells... - Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancerJ B Madalinska
Department of Public Health, Erasmus University, Rotterdam, The Netherlands
J Clin Oncol 19:1619-28. 2001.... - Human prostate-specific transglutaminase: a new prostatic marker with a unique distribution patternH J Dubbink
Department of Urology, Josephine Nefkens Institute, Erasmus University, Rotterdam, The Netherlands
Lab Invest 79:141-50. 1999..The expression pattern as observed for hTGp has not been found thus far for any other prostate-specific marker... - Attachment sites for particles in the urinary tractC F Verkoelen
Department of Urology, Erasmus University and Academic Hospital Dijkzigt, Rotterdam, The Netherlands
J Am Soc Nephrol 10:S430-5. 1999.... - Watchful waiting in prostate cancer: review and policy proposalsF H Schroder
Department of Urology, Erasmus MC, Rotterdam, The Netherlands
BJU Int 92:851-9. 2003 - Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancerStijn H de Vries
Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
Urology 65:926-30. 2005.... - Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened menR Postma
Department of Urology, Josephine Nefkens Institute, Erasmus Medical Center, Rotterdam, The Netherlands
Urology 65:745-9. 2005.... - Prostate cancer: natural history and surgical treatment of localised diseaseF H Schroder
Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
Eur J Cancer 37:S127-36. 2001..Encouragement comes from the increasing volume of evidence showing that poorly differentiated disease can be eradicated as long as it is locally confined... - The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancerA N Vis
Department of Pathology, Josephine Nefkens Institute, Erasmus University, 3000 DR Rotterdam, The Netherlands
Cancer 92:524-34. 2001..The authors assessed whether diagnostic follow-up of men with an initial diagnosis of isolated, high-grade prostatic intraepithelial neoplasia (HPIN) and a prostate biopsy suspicious for malignancy (PBSM) is needed... - Screening for prostate cancerR Postma
Department of Urology, Josephine Nefkens Institute, Erasmus MC, P O Box 1738, 3000 DR, Rotterdam, The Netherlands
Eur J Cancer 41:825-33. 2005..Therefore, until more evidence is available proving otherwise, prostate cancer screening can only be justified in the context of clinical trials... 
The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancerC Gosselaar
Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
Prostate 68:985-93. 2008....- Zeta potential measurement and particle size analysis for a better understanding of urinary inhibitors of calcium oxalate crystallizationL C Cao
Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
Scanning Microsc 10:401-11; discussion 412-4. 1996.... - Cell cultures and nephrolithiasisC F Verkoelen
Department of Urology, Erasmus University, Rotterdam, The Netherlands
World J Urol 15:229-35. 1997..Experimental studies that have been performed with cultured renal cells to elucidate the mechanisms involved in these processes will be summarized... - Antiandrogenic substances in the management of prostatic cancerF H Schroder
Department of Urology, Erasmus University, Rotterdam, The Netherlands
Recent Results Cancer Res 118:163-73. 1990..The use of antiandrogens is recommended during the initial 4 weeks of management of prostatic carcinoma patients with LH-RH agonists to prevent disease flare-up and to achieve higher early response rates in selective patients... - Decreased expression of CD44 in metastatic prostate cancerM A Noordzij
Department of Urology, Erasmus University, Rotterdam, The Netherlands
Int J Cancer 84:478-83. 1999..This reduction may be used to predict the N stage clinically, provided that CD44 scores can be determined reliably on preoperative biopsy specimens... - Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteinsJ P van Brussel
Department of Urology, Erasmus University, Rotterdam, The Netherlands
Eur J Cancer 35:664-71. 1999..Future functional studies, using chemo-selected MDR models, may further help to determine the mechanism or combination of mechanisms underlying the resistance of prostate cancer to chemotherapy... - Biomarkers and screening for prostate cancerF H Schroder
Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
Ann Oncol 17:x201-6. 2006 - Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiationJ Jongsma
Department of Experimental Urology, Josephine Nefkens Institute, Erasmus University, Rotterdam, The Netherlands
Cancer Res 60:741-8. 2000.... - Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative groupMonique J Roobol
Department of Urology, Erasmus University Medical Centre, P O Box 2010, 3000 CA, Rotterdam, The Netherlands
World J Urol 30:149-55. 2012..To compare the predictive performance and potential clinical usefulness of risk calculators of the European Randomized Study of Screening for Prostate Cancer (ERSPC RC) with and without information on prostate volume... - Blinded and uniform causes of death verification in cancer screening: a major influence on the outcome of a prostate cancer screening trial?S J Otto
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Eur J Cancer 46:3061-7. 2010.... - Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of CancerF H Schroder
Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
Br J Cancer 82:283-90. 2000..Hepatic toxicity may limit the long-term use of both drugs... - Very late local recurrence after surgery for prostate cancer unaccompanied by detectable PSA levelsS Roemeling
Department of Urology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
Prostate Cancer Prostatic Dis 9:192-4. 2006..In such exceptional cases, however, PC recurrence would be either missed or would only be diagnosed after a considerable delay... - Prediction of indolent prostate cancer: validation and updating of a prognostic nomogramE W Steyerberg
Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
J Urol 177:107-12; discussion 112. 2007..Statistical models have been proposed to predict indolent cancer. We validated and updated model predictions for a screening setting... - The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancerC H Bangma
Department of Urology, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands
BJU Int 93:720-4. 2004.... - Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands)M J Roobol
Erasmus Medical Centre, Department of Urology, Rotterdam, The Netherlands
BJU Int 92:48-54. 2003.... - Words of wisdom. Re: Statin drugs and risk of advanced prostate cancer (PC)F H Schroder
Erasmus Medical Centre, Rotterdam, The Netherlands
Eur Urol 52:1258-9. 2007 - Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policyStijn H de Vries
Department of Urology, Erasmus Medical Center and Comprehensive Cancer Center, Rotterdam, The Netherlands
J Urol 172:2193-6. 2004..We evaluated prostate cancer (PCa) characteristics at diagnosis and changes in prostatic specific antigen (PSA) with time in males with screening detected PCa that was initially managed with a watchful waiting policy... - Adjuvant endocrine treatment in early prostatic cancerF H Schroder
Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
Acta Oncol 30:255-8. 1991..It is unknown at present whether very early adjuvant treatment may prevent the progression and the promotion of focal disease to clinical prostate cancer. This possibility should be made a subject of future research... - Cell type-specific acquired protection from crystal adherence by renal tubule cells in cultureC F Verkoelen
Department of Urology, Erasmus University, Rotterdam, The Netherlands
Kidney Int 55:1426-33. 1999..We now examined whether this property is cell type specific. The susceptibility of the cells to crystal binding was further studied under different culture conditions...